Investor Alert

New York Markets Open in:

Apellis Pharmaceuticals Inc.



Before the Bell

 --Quotes are delayed by 20 min

Jun 28, 2022, 8:31 a.m.





-0.39 -0.84%


Volume 50

Quotes are delayed by 20 min


Previous close

$ 46.39

$ 46.39


+0.13 +0.28%

Day low

Day high




52 week low

52 week high




Annual Financials for Apellis Pharmaceuticals Inc.

Operating Activities

Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Net Income before Extraordinaries (51.01M)(127.5M)(304.71M)(344.87M)(746.35M)
Depreciation, Depletion & Amortization 11,935-595,449859,0001.49M
Depreciation and Depletion --595,449859,0001.49M
Amortization of Intangible Assets 11,935----
Deferred Taxes & Investment Tax Credit -----
Deferred Taxes -----
Investment Tax Credit -----
Other Funds 5.59M8.28M39.83M163.94M275.26M
Funds from Operations (45.41M)(119.22M)(264.29M)(180.07M)(469.6M)
Extraordinaries -----
Changes in Working Capital (1.19M)(12.04M)53.15M19.59M(93.52M)
Receivables ----(10.1M)
Accounts Payable --(1.64M)(54,000)10.49M
Other Assets/Liabilities (2.99M)(14.27M)4.34M(35.41M)(67.2M)
Net Operating Cash Flow (46.6M)(131.26M)(211.14M)(160.49M)(563.13M)

Investing Activities

20172018201920202021 5-year trend
Capital Expenditures --(1.69M)(5.42M)(1.1M)
Capital Expenditures (Fixed Assets) --(1.69M)(5.42M)(1.1M)
Capital Expenditures (Other Assets) -----
Net Assets from Acquisitions -----
Sale of Fixed Assets & Businesses -----
Purchase/Sale of Investments ---(311.57M)248.72M
Purchase of Investments ---(879.07M)(171.28M)
Sale/Maturity of Investments ---567.5M420M
Other Uses -----
Other Sources -----
Net Investing Cash Flow --(1.69M)(316.99M)247.62M

Financing Activities

20172018201920202021 5-year trend
Cash Dividends Paid - Total -----
Common Dividends -----
Preferred Dividends -----
Change in Capital Stock 171.01M131.92M112.71M392.42M398.02M
Repurchase of Common & Preferred Stk. -----
Sale of Common & Preferred Stock 171.01M131.92M112.71M392.42M398.02M
Proceeds from Stock Options 169.81M131.19M109.58M383M383.33M
Other Proceeds from Sale of Stock 1.2M727,5103.13M9.42M14.69M
Issuance/Reduction of Debt, Net 26.36M-184.21M322.87M-
Change in Current Debt -----
Change in Long-Term Debt 26.36M-184.21M322.87M-
Issuance of Long-Term Debt 26.36M-212.91M322.87M-
Reduction in Long-Term Debt --(28.7M)--
Other Funds --91.62M(23.11M)(5.79M)
Other Uses --(28.38M)(43.11M)(5.79M)
Other Sources --120M20M-
Net Financing Cash Flow 197.38M131.92M388.54M692.18M392.24M
Exchange Rate Effect -(38,426)4,702359,000(2.02M)
Miscellaneous Funds -----
Net Change in Cash 150.78M624,137175.72M215.06M74.71M
Free Cash Flow (46.6M)(131.26M)(212.83M)(165.91M)(564.23M)
Link to MarketWatch's Slice.